Articles On Imugene (ASX:IMU)

A little-known ASX All Ords share is setting the bar high today. In afternoon trade on Monday, the All Ordinaries Index (ASX: XAO) is down 0.8%. But this ASX All Ords share is heading the other way, up 7% at the time of writing to $2.06...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to start the week with a disappointing decline. The benchmark index is currently down 0.9% to 7,272.1 points. Four ASX shares that are not letting that hold them back a...

Imugene (IMU) VAXINIA trial is moving ahead to cohort four The company is effectively de-risking its product with each successful step forward in the phase one trial VAXINIA seeks to kill solid cancers in the body using a virus as op...

The Imugene Ltd (ASX: IMU) share price is leaping higher today. Shares in the S&P/ASX 200 Index (ASX: XJO) biotechnology company closed on Friday trading for 89 cents. During the lunch hour on Monday, shares are swapping hands for 94 c...

Anteris Tech’s DurAVR THV was implanted successfully in a procedure Imugene moves forward to cohort 4 in VAXINIA study MGC Pharma says CimetraA has no toxicology profile in large animals   Anteris’ DurAVR THV implanted successfully Anteri...

Clinical stage immuno-oncology company Imugene (ASX: IMU) has announced that a Phase 1 MAST (metastatic advanced solid tumours) trial evaluating the safety of novel cancer-killing virus CF33-hNIS (Vaxinia) has cleared the cohort 3 intratumo...

Highlights Imugene’s VAXINIA MAST trial has cleared cohort 3 IT monotherapy dose escalation study. With this development, Imugene can recruit for IT cohort 4 of the monotherapy dose escalation. In cohort 4, VAXINA will be administered...

The Carsales.Com Ltd (ASX: CAR) share price is on the move on Monday. At the time of writing, the auto listings company’s shares are up over 5% to a 52-week high of $26.00. This follows the release of the company’s FY 2023 results this m...

Futures suggest the ASX will open in the red this morning, ahead of fresh ABS wage data, which will be released tomorrow, and July’s jobs report to follow on Thursday. Nonetheless, here are some ASX-listed companies with news out today:...

The Renascor Resources Ltd (ASX: RNU) share price is down 3.6% today despite another positive update. The shares are currently sitting at 14 cents apiece. They took a 23% dive yesterday despite the ASX mineral explorer announcing “compel...

The Renascor Resources Ltd (ASX: RNU) share price is down 21% over the past two days following an update on the mineral explorer’s proposed Siviour Battery Anode Material (BAM) project. Renascor Resources owns the Siviour Graphite Deposit...

The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July   The Covid-19 pandemic had produced windfalls for and attracted fa...

Futures suggest the ASX will open lower today as investors contemplate the unexpected downgrade of the USA’s top-tier sovereign credit rating. Tech shares have reigned in ahead of earnings from Apple and Amazon, which are expected this F...

Whilst the prevalence of Artificial intelligence has boosted the US-tech sector, with the likes of Nvidia and C3.ai seeing their share prices increase by 219% and 265% respectively since the start of the year, Down Under, tech stock valuati...

LOS ALTOS, CA, USA, July 20, 2023/EINPresswire.com/ -- RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion (TAMP™) Platform • Collaboration will explore trans-arte...

Imugene (IMU) enters a strategic research collaboration with RenovoRx to optimise the delivery of its oncolytic virotherapy for the treatment of difficult-to-access tumours Using RenovoRx’ TAMP therapy, IMU will investigate the ability t...

Highlights Imugene has formed a partnership with clinical-stage biopharmaceutical firm – RenovoRx for its oncolytic virus therapy. The collaboration will assess the ability to administer the CF33 oncolytic virus technology with the TAM...

This content is created by Smallcaps Authors. [Author : Imelda Cotton] Clinical-stage immuno-oncology company Imugene (ASX: IMU) and US biopharmaceutical company RenovoRx Inc have formed a strategic research collaboration to optimise the...

World Overnight SPI Overnight 7286.00 + 2.00 0.03% S&P ASX 200 7323.70 + 39.90 0.55% S&P500 4565.72 + 10.74 0.24% Nasdaq Comp 14358.02 + 4.38 0.03% DJIA 35061.21 + 109.28 0.31% S&P500 VIX 13.76 + 0.46 3.46% US 10...

Finally, a positive day for the S&P/ASX 200 Index (ASX: XJO)! After falling in both Monday and Tuesday’s sessions, this week was turning out to be a rather depressing one. Thankfully, the ASX 200 turned a corner this Wednesday and d...

The Energy sector demonstrated strong growth, with a rally of 1.7%. Ampol (ASX:ALD) experienced a significant surge of 4.4% following robust fuel sale volumes reported for the first half of the financial year 2023. Woodside Petroleum (ASX:W...

This content is created by Smallcaps Authors. [Author : Imelda Cotton] Clinical stage immuno-oncology company Imugene (ASX: IMU) has received a notice of allowance from the US Patent and Trademark Office for a patent to protects its prima...

Imugene (IMU) receives US patent approval to protect its oncolytic virotherapy CF33, including VAXINIA and CHECKVacc The patent, “Chimeric Poxvirus Composition and Uses Thereof”, protects the company’s method of composition and treatment...

Woodside Energy (ASX:WPL), reported a 29% decline in revenue for the second quarter, amounting to $US3.1 billion (A$4.5 billion). Sales of oil decreased by 4%, with 48.4 million barrels sold, while production experienced a 5% drop to 44.5 m...

Highlights Imugene has secured a patent for its licenced oncolytic virotherapy in the United States. Oncolytic virotherapy CF33 comprises CHECKVacc and VAXINIA. The patent protects the composition and usage methodology of the oncolyti...

The Peninsula Energy Ltd (ASX: PEN) share price is having a day to forget on Wednesday. At one stage today, the ASX All Ordinaries share was down as much as 30% to 12.5 cents. It has since bounced back a touch but remains down 22% at 14 ce...

The Imugene Ltd (ASX: IMU) share price is leaping higher today, up 7.5% at the time of writing. Shares in the S&P/ASX 200 Index (ASX: XJO) biotechnology company closed yesterday trading for 9.3 cents. Shares are currently swapping hand...

  ImpediMed (ASX:IPD) are the first top 5 national payor covering SOZO testing for cancer patients at risk for lymphoedema. In response, CEO and MD Richard Valencia said, ”Cigna’s policy provides access to coverage for all individuals at ri...

The BetaShares Australian Dividend Harvester Fund (ASX: HVST) is one of the more popular high-yield ASX exchange-traded funds (ETFs) that investors can buy to aim for high dividend yields. Some ETFs can be focused on holding businesses for...

Highlights Imugene has appointed Dr Ron Weitzman as its interim CMO. Dr Weitzman has an experience of over 20 years in the biopharmaceutical space. Dr Weitzman has extensive record in clinical development plan development and executio...

19 Jul 2023 - A snapshot of the stocks on the move, featuring ImpediMed (ASX:IPD), Imugene Limited (ASX:IMU) and Brightstar Resources (ASX:BTR).

Tim Boreham highlights the potential for cancer treatment biotech Arovella Therapeutics. By Tim Boreham ASX code: ((ALA)) Share price: 4.8 cents Shares on issue: 899,149,698 Market cap: $44 million Chief executive officer: Dr Michael Baker...

The fund manager L1 Capital has identified two S&P/ASX 200 Index (ASX: XJO) shares that could be great value opportunities to invest in. L1 is still cautious on the outlook for the stock market “given the looming impact of significan...

The ASX 200 is down nearly 0.5 per cent at market close, declining throughout the day after a strong start.  Information Technology was the only sector to hold up in the green, with Vista Group, Echo IQ, Bigtincan Holdings, Orcoda, ArchT...

This content is created by Smallcaps Authors. [Author : Colin Hay] Clinical stage immuno-oncology company Imugene (ASX: IMU) has confirmed that the world-renowned City of Hope independent cancer research and treatment centre will lead a t...

Imugene (IMU) to proceed with a fourth dose cohort in the phase one trial of its oncolytic virotherapy candidate, CHECKvacc Independent cancer research centre City of Hope reported no toxic effects to date IMU CEO Leslie Chong says th...

Highlights Phase I clinical trial of CHECKvacc is set to proceed to the fourth dose cohort. The trial of the oncolytic virotherapy candidate is designed to treat patients with triple negative breast cancer (TNBC). The study focuses on...

The Vulcan Energy Resources Ltd (ASX: VUL) share price is pushing higher again on Tuesday. In afternoon trade, the lithium developer’s shares are up 6% to $4.55. This means the company’s shares are now up 20% since this time last week....

It’s been a bumpy but overall positive end for the S&P/ASX 200 Index (ASX: XJO) for this Friday, this week and for the 2023 financial year. The ASX 200 has finished up in the green today, recording a gain of 0.12%. That puts the ind...

ASX value shares and growth shares both went up in FY23, but value stocks did a bit better. The S&P/ASX 200 Value Index is up 8.32% in the financial year to date. If you take dividends into account, the total return for FY23 is 13.55%...

It’s the last day of the financial year and significant changes are set to take place from tomorrow. Australia’s minimum wage will increase to just above $23 per hour. Superannuation figures will also increase from 10.5 per cent to 11 p...

The S&P/ASX 200 Index (ASX: XJO) is on course to finish the week with a small decline. At the time of writing, the benchmark index is down slightly to 7,192.5 points. Four ASX shares that are not letting that hold them back today are...

Highlights Imugene’s new and significant HER-Vaxx data has been presented at the World Congress of Gastrointestinal Cancer in Barcelona. The abstract presented was about ‘HERIZON: A Phase 2 study of HER-Vaxx (IMU-131)’. The World Con...

Imugene (IMU) presents “new and significant” HER-Vaxx data at the World Congress of Gastrointestinal Cancer in Barcelona The company reported its HER-Vaxx-induced antibodies correlated with tumour reduction in patients with advanced stom...

ASX set to open lower this morning after a slow day on Wall Street overnight. ASX 200 Futures Index was in a fickle mood all morning, hovering around zero change. Health tech Immugene has some huge news from a major conference in Barcelona...

This content is created by Smallcaps Authors. [Author : Imelda Cotton] Clinical stage immuno-oncology company Imugene (ASX: IMU) has introduced “new and significant data” relating to lead candidate HER-Vaxx to delegates at the World Congr...

There were 432,000 job vacancies in May 2023 – 9,000 less than in February. The Australian Bureau of Statistics this morning revealed the two per cent drop, marking the fourth consecutive quarterly fall in available jobs. However, whi...

Imugene (IMU) receives an extension of its PD1-Vaxx patent from the United States Patent Office until 2040 The patent titled, “HUMAN PD1 Peptide Vaccines And Uses Thereof”, includes 685 days of patent term adjustments to its original exp...

Highlights The United States Patent Office has awarded a patent to the company’s immunotherapeutic PD1-Vaxx. The vaccine is being designed for patients with non-small cell lung cancer (NSCLC). The patent will expire in 2040. Clini...

This content is created by Smallcaps Authors. [Author : Imelda Cotton] Clinical stage immuno-oncology company Imugene (ASX: IMU) has been granted a patent extension by the US Patent Office to protect its immunotherapeutic PD1-Vaxx for the...